OXFORD, United Kingdom, and BALTIMORE, Dec. 13, 2021 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines, today announced that it has acquired US-based Avidea Technologies, Inc. (“Avidea”).
The consideration to Avidea’s existing shareholders is $40 million (comprised of approximately $12.5 million in cash and $27.5 million in Vaccitech American Depository Shares) in addition to potential future payments that are conditioned upon the achievement of certain development milestones.
{iframe}https://www.globenewswire.com/news-release/2021/12/13/2351152/0/en/Vaccitech-acquires-Avidea-Technologies-to-expand-product-pipeline-and-strengthen-scientific-leadership-in-immunotherapies-and-vaccines.html{/iframe}